<b><span style="font-family:Verdana;">Objective</span></b><span style="font-family:Verdana;">:</span><span><span style="font-family:Verdana;"&...<b><span style="font-family:Verdana;">Objective</span></b><span style="font-family:Verdana;">:</span><span><span style="font-family:Verdana;"> To explore the effects of Danqi Yishen Capsule (Danqi Capsule for Tonifying Kidney) on blood lipid levels and hemorheological indicators of hyperlipidemia patients. </span><span><span style="font-family:Verdana;"><b></b></span><b><b><span style="font-family:Verdana;">Methods</span></b></b></span></span><b><span style="font-family:Verdana;">:</span></b><b><span> </span></b><span style="font-family:Verdana;">A total of 96 patients </span><span style="font-family:Verdana;">with</span><span style="font-family:Verdana;"> hyperlipidemia were randomly divided into </span><span style="font-family:Verdana;">the </span><span style="font-family:Verdana;">control group and observation group of 48 cases respectively. The control group was given by simvastatin in oral administration of 10 mg half an hour after dinner, once a day, while the observation group based on the treatment of </span><span style="font-family:Verdana;">the </span><span style="font-family:Verdana;">control group, was orally given Danshen Yishen Capsule of three capsules each time, three times a day. The treatment of both groups lasted for two months. Then the comparison focused on blood lipid levels, hemorheological indicators</span><span style="font-family:Verdana;">,</span><span><span style="font-family:Verdana;"> and adverse reactions between both groups before and after the treatment. </span><span><span style="font-family:Verdana;"><b></b></span><b><b><span style="font-family:Verdana;">Results</span></b></b></span></span><b><span style="font-family:Verdana;">:</span></b><span> </span><span style="font-family:Verdana;">There was no significant difference</span><span><span style="font-family:Verdana;"> in blood lipid levels and hemorheological indicators between both groups before the treatment (<i></i></span><i><i><span style="font-family:Verdana;">P</span></i><span style="font-family:Verdana;"></span></i></span><i><span> </span></i><span><span style="font-family:Verdana;">> 0.05). The symptoms of both groups were significantly improved after the treatment, and the difference before and after the treatment was statistically significant (<i></i></span><i><i><span style="font-family:Verdana;">P</span></i><span style="font-family:Verdana;"></span></i></span><span> </span><span><span style="font-family:Verdana;">< 0.05), and the difference between both groups was also statistically significant (<i></i></span><i><i><span style="font-family:Verdana;">P</span></i><span style="font-family:Verdana;"></span></i></span><span style="font-family:Verdana;"> < 0.05). There was no significant difference in the incidence rate of adverse reactions between both groups (<i></i></span><i><i><span style="font-family:Verdana;">P</span></i><span style="font-family:Verdana;"></span></i><span> </span><span><span style="font-family:Verdana;">> 0.05). </span><span><span style="font-family:Verdana;"><b></b></span><b><b><span style="font-family:Verdana;">Conclusion</span></b></b></span></span><b><span style="font-family:Verdana;">:</span></b><b><span> </span></b><span style="font-family:Verdana;">Danqi Yishen Capsule has a significant value in clinical applications, which can optimize clinical efficacy, improve blood lipid levels and hemorheological indicators of hyperlipidemia patients, as well as reduce the probability of adverse reactions in patients.</span>展开更多
文摘<b><span style="font-family:Verdana;">Objective</span></b><span style="font-family:Verdana;">:</span><span><span style="font-family:Verdana;"> To explore the effects of Danqi Yishen Capsule (Danqi Capsule for Tonifying Kidney) on blood lipid levels and hemorheological indicators of hyperlipidemia patients. </span><span><span style="font-family:Verdana;"><b></b></span><b><b><span style="font-family:Verdana;">Methods</span></b></b></span></span><b><span style="font-family:Verdana;">:</span></b><b><span> </span></b><span style="font-family:Verdana;">A total of 96 patients </span><span style="font-family:Verdana;">with</span><span style="font-family:Verdana;"> hyperlipidemia were randomly divided into </span><span style="font-family:Verdana;">the </span><span style="font-family:Verdana;">control group and observation group of 48 cases respectively. The control group was given by simvastatin in oral administration of 10 mg half an hour after dinner, once a day, while the observation group based on the treatment of </span><span style="font-family:Verdana;">the </span><span style="font-family:Verdana;">control group, was orally given Danshen Yishen Capsule of three capsules each time, three times a day. The treatment of both groups lasted for two months. Then the comparison focused on blood lipid levels, hemorheological indicators</span><span style="font-family:Verdana;">,</span><span><span style="font-family:Verdana;"> and adverse reactions between both groups before and after the treatment. </span><span><span style="font-family:Verdana;"><b></b></span><b><b><span style="font-family:Verdana;">Results</span></b></b></span></span><b><span style="font-family:Verdana;">:</span></b><span> </span><span style="font-family:Verdana;">There was no significant difference</span><span><span style="font-family:Verdana;"> in blood lipid levels and hemorheological indicators between both groups before the treatment (<i></i></span><i><i><span style="font-family:Verdana;">P</span></i><span style="font-family:Verdana;"></span></i></span><i><span> </span></i><span><span style="font-family:Verdana;">> 0.05). The symptoms of both groups were significantly improved after the treatment, and the difference before and after the treatment was statistically significant (<i></i></span><i><i><span style="font-family:Verdana;">P</span></i><span style="font-family:Verdana;"></span></i></span><span> </span><span><span style="font-family:Verdana;">< 0.05), and the difference between both groups was also statistically significant (<i></i></span><i><i><span style="font-family:Verdana;">P</span></i><span style="font-family:Verdana;"></span></i></span><span style="font-family:Verdana;"> < 0.05). There was no significant difference in the incidence rate of adverse reactions between both groups (<i></i></span><i><i><span style="font-family:Verdana;">P</span></i><span style="font-family:Verdana;"></span></i><span> </span><span><span style="font-family:Verdana;">> 0.05). </span><span><span style="font-family:Verdana;"><b></b></span><b><b><span style="font-family:Verdana;">Conclusion</span></b></b></span></span><b><span style="font-family:Verdana;">:</span></b><b><span> </span></b><span style="font-family:Verdana;">Danqi Yishen Capsule has a significant value in clinical applications, which can optimize clinical efficacy, improve blood lipid levels and hemorheological indicators of hyperlipidemia patients, as well as reduce the probability of adverse reactions in patients.</span>